The large molecule drug substance CDMO market is anticipated to expand at a CAGR of ~9% during the forecast period. Key ...

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and ...

Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- ...

Alvotech is expanding its partnership with Advanz Pharma to commercialize new products in Europe, including a Kesimpta ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

Kaddis said insurers are locked in a cat-and-mouse game with drugmakers as the insurance sector invests in biosimilars and ...

From five years of sales declines to nine consecutive quarters of growth, it’s hard to deny that Teva’s revamp under CEO Richard Francis is paying off. | By 2030, Teva now expects to achieve at least ...